GetTopicDetailResponse(id=ef96939538, topicName=Idarucizumab, introduction=Idarucizumab, content=null, image=null, comments=3, allHits=1039, url=https://h5.medsci.cn/topic?id=9395, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=28079, tagList=[TagDto(tagId=28079, tagName=Idarucizumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2077284, encodeId=16ec20e728490, content=<a href='/topic/show?id=ef96939538' target=_blank style='color:#2F92EE;'>#Idarucizumab#</a>, objectTitle=IJLH：在常規(guī)凝血分析中，達比加群的吸附與添加idarucizumab以中和藥物一樣有效, objectType=article, longId=145620, objectId=2c1114562020, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c1114562020, replyNumber=0, likeNumber=88, createdTime=2019-05-21, rootId=0, userName=ms920641618706883, userId=aa5a2500103, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c1114562020, moduleTitle=IJLH：在常規(guī)凝血分析中，達比加群的吸附與添加idarucizumab以中和藥物一樣有效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2c1114562020)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077283, encodeId=dcc320e72834e, content=<a href='/topic/show?id=ef96939538' target=_blank style='color:#2F92EE;'>#Idarucizumab#</a>, objectTitle=Lancet：Idarucizumab可在5分鐘內(nèi)逆轉(zhuǎn)達比加群作用，且耐受良好, objectType=article, longId=54622, objectId=ecc754622f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecc754622f7, replyNumber=0, likeNumber=102, createdTime=2015-10-18, rootId=0, userName=ms920641618706883, userId=aa5a2500103, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecc754622f7, moduleTitle=Lancet：Idarucizumab可在5分鐘內(nèi)逆轉(zhuǎn)達比加群作用，且耐受良好, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ecc754622f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077282, encodeId=172f20e728222, content=<a href='/topic/show?id=ef96939538' target=_blank style='color:#2F92EE;'>#Idarucizumab#</a>, objectTitle=NEJM：Idarucizumab在使用達比加群數(shù)分鐘內(nèi)能夠完全逆轉(zhuǎn)抗凝作用, objectType=article, longId=54621, objectId=acdc546216f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acdc546216f, replyNumber=0, likeNumber=87, createdTime=2016-01-10, rootId=0, userName=ms920641618706883, userId=aa5a2500103, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acdc546216f, moduleTitle=NEJM：Idarucizumab在使用達比加群數(shù)分鐘內(nèi)能夠完全逆轉(zhuǎn)抗凝作用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=acdc546216f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
